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Abstract: The altered nitric oxide (NO) pathway in the pulmonary endothelium leads to in-
creased vascular smooth muscle tone and vascular remodelling, and thus contributes to the 
development and progression of pulmonary arterial hypertension (PAH). The pulmonary NO 
signalling is abrogated by the decreased expression and dysfunction of the endothelial NO 
synthase (eNOS) and the accumulation of factors blocking eNOS functionality. The NO defi-
ciency of the pulmonary vasculature can be assessed by detecting nitric oxide in the exhaled 
breath or measuring the degradation products of NO (nitrite, nitrate, S-nitrosothiol) in blood 
or urine. These non-invasive biomarkers might show the potential to correlate with changes in 
pulmonary haemodynamics and predict response to therapies. Current pharmacological thera-
pies aim to stimulate pulmonary NO signalling by suppressing the degradation of NO (phos-
phodiesterase-5 inhibitors) or increasing the formation of the endothelial cyclic guanosine 
monophosphate, which mediates the downstream effects of the pathway (soluble guanylate 
cyclase sensitizers). Recent data support that nitrite compounds and dietary supplements rich 
in nitrate might increase pulmonary NO availability and lessen vascular resistance. This re-
view summarizes current knowledge on the involvement of the NO pathway in the pathome-
chanism of PAH, explores novel and easy-to-detect biomarkers of the pulmonary NO. 
Keywords: Pulmonary arterial hypertension, nitric oxide, nitric oxide synthase, FENO, biomarkers, systemic scle-
rosis. 
1. INTRODUCTION 
Pulmonary hypertension (PH) is defined as an in-
creased mean pulmonary arterial pressure (mPAP ≥ 25 
mmHg) measured during right heart catheterization. 
Patients with PH are classified into five groups based 
on clinical presentation, haemodynamic parameters, 
pathological alterations and treatment strategies (Table 
1) [1]. These groups show different survival trajectories 
and aetiological backgrounds. Pulmonary arterial hy-
pertension (PAH), group 1, is a rare and progressive 
form with currently no cure and an average survival 
rate of less than 3 years without treatment [2].  
Various subgroups of PAH have been reported in-
cluding the idiopathic, the hereditary, the drug- and  
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toxin-induced variants and those associated with other 
diseases, most commonly with connective tissues dis-
eases such as systemic sclerosis (SSc) and congenital 
heart disease [1] (Table 1).  
In PAH, the pulmonary vascular resistance is ele-
vated (PVR > 3 Wood units), and pathological altera-
tions in the pre-capillary pulmonary vasculature are 
characteristic [1]. It is described by vascular remodel-
ling, including medial hypertrophy and hyperplasia, 
intimal and adventitial fibrosis, plexiform and throm-
botic lesions, which mainly affect the distal muscular 
type of pulmonary arteries [3]. These alterations result 
in gradually increasing PVR and right ventricular after-
load leading to decreased cardiac output, which can be 
initially compensated by the adaptive processes of the 
right ventricle. The preservation of the right ventricular 
function is a major therapeutic goal in PAH, as right 
heart failure is a key determinant of survival [4].  
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Table 1. Clinical classification of pulmonary hypertension (simplified from Galie et al.[1]). 
Group 
Number 
Name of the Group Subgroups 
1 Pulmonary arterial  
hypertension 
1.1. Idiopathic 
1.2. Heritable 
1.3. Drugs- and toxin-induced (e.g. anorexigens including aminorex, fenfluramine, dex-
fenfluramine and benfluorex; toxic rapeseed oil; selective serotonine reuptake inhibitors) 
1.4. Associated with  
1.4.1. connective tissue disease (e.g. systemic sclerosis) 
1.4.2. HIV infection 
1.4.3. portal hypertension 
1.4.4. congenital heart disease 
1.4.5. schistosomiasis 
2 PH due to left heart disease Most commonly patients with systolic or diastolic left ventricular dysfunction or valvular 
disease 
3 PH due to lung diseases 
and/or hypoxia 
Including patients with COPD, interstitial lung disease, sleep-disordered breathing, alveo-
lar hypoventilation or chronic exposure to high altitude 
4 Chronic thromboembolic PH 
and other pulmonary artery 
obstructions 
Other pulmonary artery obstructions include angiosarcoma, intravascular tumors and 
congenital pulmonary artery stenoses 
5 PH with unclear and/or mul-
tifactorial mechanisms 
Such as patients with haematological, systemic or metabolic disorders 
COPD: chronic obstructive pulmonary disease, HIV: human immunodeficiency virus, PH: pulmonary hypertension. 
All layers of distal pulmonary arteries undergo vas-
cular remodelling in PAH manifested in structural 
changes in the endothelium (concentric intimal fibrosis, 
endothelial cell proliferation resulting in plexiform le-
sions), medial layer (proliferation of smooth muscle 
cells) and adventitia (fibrous broadening, perivascular 
inflammation, appearance of tertiary lymphoid tissue). 
Adapted from Dorfmüller et al.[5].  
Genetic predispositions together with pathological 
triggers, i.e. inflammatory stimuli, oxidative stress, hy-
poxia, mechanical strain and altered cellular metabo-
lism, induce the remodelling and dysfunction of all 
layers of the pulmonary arteries [3], with endothelial 
injury being the main disease driver (Fig. 1). Endothe-
lial dysfunction in PAH mostly refers to the imbalance 
between the production of endothelium-derived vaso-
constrictive and vasodilatory molecules. Nonetheless, 
the dysfunction also denotes other metabolic changes 
in endothelial cells including reduced anticoagulant 
properties, altered proliferative capacity, sensitivity to 
apoptosis, the altered production of reactive oxygen 
species, cytokines and chemokines. Increased cytosolic 
calcium (Ca2+) concentration is an important factor in 
the pathomechanism of pulmonary vasoconstriction 
and endothelial dysfunction in PAH. Calcium sensing 
receptor (CaSR) is expressed on pulmonary artery 
smooth cells and it regulates intracellular Ca2+ concen-
tration due to monitoring extracellular Ca2+ levels [6]. 
Experimental models of PAH have demonstrated over-
expression of CaSR contributing to extracellular Ca2+-
induced elevation in intracellular Ca2+ concentration 
and proliferation of smooth vascular cells in the lung 
by regulating several signalling pathways [7]. How-
ever, the exact causes and mechanisms of endothelial 
dysfunction in PAH are still not wholly understood.  
The diagnosis of PAH is delayed in most cases due 
to the unspecific symptoms (most commonly dyspnoea, 
syncope and chest pain) and the lack of easy-to-use 
diagnostic measures [8]. Large cohort studies have 
proved that the survival of patients has considerably 
improved since the introduction of specific PAH thera-
pies [9], however, the rate of disease progression shows 
higher individual differences and initiating the right 
treatment at the right time is crucial in disease man-
agement. Current treatment modalities target the inhibi-
tion of endothelial vasoconstrictive pathways (endo-
thelin receptor antagonists e.g. bosentan, ambrisentan) 
or aim to induce vasodilatory signals via the nitric ox-
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ide pathway (e.g. tadalafil, sildenafil) or prostacyclin 
signalling (e.g. epoprostenol, treprostinil) [1].  
The dampened nitric oxide (NO) pathway is a major 
player in endothelial dysfunction, and drugs upregulat-
ing this process are at the forefront of recommended 
therapies [1]. However, the involvement of NO signal-
ling can be different in individual patients with PAH, 
and the therapeutic response cannot be fully predicted 
in advance besides some unspecific clinical factors 
such as age, sex, functional capacity and disease aetiol-
ogy [10]. The treatment effect of drugs can be meas-
ured by the change in haemodynamic parameters using 
the invasive right heart catheterization, which is bur-
densome for patients and requires sophisticated meas-
urement techniques.  
Hence, there is an urgent need to find non-invasive 
biomarkers to aid diagnosis, predict therapeutic re-
sponse and guide treatments. This review summarizes 
the current knowledge on the involvement of endothe-
lial NO signalling in the pathomechanism of PAH and 
discusses the application of non-invasive markers to 
assess the endothelial NO pathway - with focus on ex-
haled NO – with the aim to facilitate disease diagnosis 
and monitoring.  
2. ALTERED NITRIC OXIDE SIGNALLING IN 
PAH  
2.1. The NO Signalling Pathway in the Pulmonary 
Vasculature  
The pulmonary circulation is the low resistance part 
of the circulatory system which carries deoxygenated, 
carbon dioxide-rich blood from the right heart to the 
lungs and returns oxygen-rich blood to the left heart 
[11]. The vascular tone is maintained by the balance of 
vasoconstrictive (i.e. endothelin-1, serotonin, etc.) and 
vasodilator (prostacyclin and nitric oxide) mediators. 
Nitric oxide (NO) is a highly soluble free radical 
gas which is produced from L-arginine during its con-
version to L-citrulline by nitric oxide synthases (NOS, 
Fig. 2). Tetrahydrobiopterin (BH4) is an important cata-
lysator for this reaction, and the lack of BH4 is associ-
ated with uncoupling of NOS, decreased NO and in-
creased superoxide production [11]. The three NOS 
isoenzymes include neuronal NOS (NOS1 or nNOS), 
inducible NOS (NOS2 or iNOS) and endothelial NOS 
(NOS3 or eNOS). eNOS is mainly expressed in the 
vascular endothelium and it is the main source for NO 
in the pulmonary circulation [11]. However, other cells 
in the lungs, such as alveolar type II cells [12] and al-
veolar macrophages [13] express eNOS as well. nNOS 
is expressed by the endothelium, vascular smooth mus-
cle cells and cholinergic neurons [11, 14]. Endothelial 
and neuronal isoforms of NOS are constitutively ex-
pressed and their activation depends on cal-
cium/calmodulin [15], however other factors, such as 
shear stress, hypoxia, inflammation, growth factors, 
hormones and lipoproteins may also modulate their 
expressions [16]. iNOS can be expressed by most cell 
types upon stimulation by hypoxia, inflammatory cyto-
kines or bacterial lipopolysaccharide [17]. Nitric oxide 
acts through various pathways, such as inducing the 
soluble guanylate cyclase (sGC) enzyme, oxidation of 
NO to nitrite and nitrate or reactions with protein thiols 
to form S-nitrosothiols. NO exerts its well-known 
smooth muscle relaxation effect through sGC by cata-
lysing the formation of cyclic guanosine monophos-
phate (cGMP) from guanosine triphosphate (GTP). 
 
Fig. (1). Main pathological alterations in pulmonary arteries in PAH. (A higher resolution / colour version of this figure is 
available in the electronic copy of the article). 
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cGMP acts through cGMP-dependent protein kinase, 
ion channels and phosphodiesterase, leading to relaxa-
tion of the smooth muscles (Fig. 2). Nitrite, nitrate and 
nitrosothiols are longer half-life metabolites of NO 
which serve as potential NO donors but they may also 
induce vasodilation in pulmonary vessels [11]. The role 
of NO depends primarily on its concentration, as in low 
levels it stimulates sGC, while in higher levels, oxida-
tion is the main pathway [18]. Further details on the 
regulation of vascular NO formation can be found in 
recently published reviews [19, 20]. 
2.2. Damage to eNOS Signalling in PAH 
Several articles have described impaired NO pro-
duction in various forms of pulmonary hypertension, 
however, with conflicting results [11, 18, 21-25]. Some 
of these discrepancies are attributed to methodological 
factors, such as interracial differences in animal stud-
ies, various measurements of NOS activity and its 
products. Experimental models to investigate NO and 
NOS activity in pulmonary vessels were discussed in 
the review article of Hampl and Herget [18]. Most im-
portantly, many studies used hypoxic challenge to in-
duce pulmonary hypertension. Chronic hypoxia can 
lead to decreased eNOS expression in pulmonary ves-
sels [26, 27], however the data are conflicting in other 
studies showing that chronic hypoxia induced the ex-
pression of all NOS isoforms [28, 29]. Nevertheless, 
the hypoxic model more closely represents group 3 
pulmonary hypertension than group 1 PAH (Table 1). 
In contrast, although monocrotaline treatment induces 
PAH-like changes in the pulmonary vessels, the toxin 
damages the liver, kidneys and the heart as well [30].  
In their elegant study, Fagan et al. selectively dis-
rupted each NOS isoform in transgenic mice. Inhibition 
of eNOS induced pulmonary hypertension, iNOS 
blockage only very mildly elevated PAP, while nNOS 
disruption did not have any effect [31]. In contrast, de-
letion of eNOS gene induced only mild pulmonary hy-
pertension in rats suggesting other responsible mecha-
nisms for vascular tone [25]. It seems that under 
physiological condition, nNOS and iNOS do not con-
tribute to the control of vascular tone. However, vascu-
lar inflammation noticed in PAH can induce iNOS [17, 
18]. Interestingly, in eNOS knock out rats, an increased 
iNOS expression and exhaled nitric oxide levels were 
reported, suggesting compensatory mechanisms [32]. 
In their seminal study, Giaid and Saleh reported de-
creased eNOS expression in patients with idiopathic 
pulmonary arterial hypertension (IPAH - group 1.1. as 
shown in Table 1). Moreover, eNOS expression was 
the lowest in plexiform lesions in the remodelled endo-
thelium [21]. This has been challenged by Mason et al. 
who found significantly increased eNOS expression in 
plexiform lesions [33], concluding considerable het-
erogeneity in eNOS appearance in patients with PAH. 
Interestingly, not only vascular, but platelet eNOS ex-
pression is also decreased in IPAH [34]. In contrast, in 
PAH associated with congenital heart defect (subgroup 
 
Fig. (2). The pharmacological modulation of NO signalling in the pulmonary vasculature. (A higher resolution / colour version 
of this figure is available in the electronic copy of the article). 
The Nitric Oxide Pathway in Pulmonary Arterial Hypertension Current Medicinal Chemistry, 2020, Vol. 27, No. 00    5 
1.4.4. in Table 1), NO concentrations in blood were 
higher in patients than in controls suggesting compen-
satory pulmonary mechanisms [35, 36]. Tuder et al. 
studied various subgroups of patients with PAH and 
found no difference in eNOS expression compared to 
controls [37]. Interestingly, eNOS expression in pul-
monary arteries can be modulated by lifestyle factors 
such as smoking, as low eNOS has been found in pul-
monary arteries of non-hypoxemic smokers as well [38, 
39]. 
The discrepancies discussed above may be related 
to the simultaneous presence of factors that up- and 
downregulate eNOS expression in PAH. Moreover, 
endothelial cell injury and plexiform regions tend to be 
topical in pulmonary arteries in PAH, contributing to 
focal differences in eNOS expression.  
Mechanisms upregulating eNOS in PAH include 
growth factors, endothelin-1 and serotonin [40-42], the 
levels of which are elevated in PAH [24]. In addition, 
pulmonary blood flow is accelerated in PAH resulting 
in sheer stress which is a potent inductor for eNOS 
[18]. Nitric oxide production can also be induced by 
the vascular endothelial growth factor (VEGF) [43] 
which is mainly produced in plexiform lesions in PAH 
and contributes to vascular remodelling [24]. 
Factors that downregulate eNOS in PAH are more 
broadly studied. Around 70% of patients with heritable 
and idiopathic PAH have mutations in the bone 
morphogenetic protein receptor II (BMPR2) gene [44]. 
BMPR2 is recognised as an important element in eNOS 
phosphorylation and upregulation [45]. Endothelial 
NOS is downregulated in proliferating endothelial cells 
and after endothelial injury [46]. Inflammation can also 
decrease eNOS production in the pulmonary arteries 
[27]. Oxidative stress can be enhanced in PAH due to 
sheer stress and perivascular inflammation, and it is 
known to reduce eNOS function by the following mo-
lecular mechanisms [47]. An important mechanism 
leading to decreased NO bioavailability is the altered 
function of eNOS. Under oxidative conditions, the ac-
tivity of eNOS is characterized by a decreased NO 
generation with concomitant superoxide anion produc-
tion. This mechanism is referred as “eNOS uncou-
pling” [48]. The depletion of BH4 is the main cause of 
eNOS uncoupling [49]. BH4 deficiency due to oxida-
tive stress was reported in several animal models of 
PAH [50, 51]. The limited availability of L-arginine, 
which is the main substrate of eNOS, is also responsi-
ble for eNOS-uncoupling [52]. Free radicals such as 
peroxynitrite can increase arginase activity resulting in 
lower L-arginine levels and consequential eNOS un-
coupling [53]. Moreover, increased levels of the L-
arginine analogue asymmetric dimethylarginine 
(ADMA) also lead to the loss of eNOS activity in PAH 
[54]. Another potential mechanism that decreases NO 
production is the posttranscriptional regulation of 
eNOS. Phosphorylation of eNOS at different specific 
sites is the main regulatory mechanism in stimulation 
or inhibition of NO production. Phosphorylation of ser-
ine 1177 (Ser1177) by serine/threonine protein kinase 
Akt/PKB results in enhanced eNOS activity [55]. 
However, phosphorylation at threonine 495 (Thr495) 
may constrain eNOS activity [56]. The inhibition of 
eNOS by abnormal Thr496 phosphorylation was con-
firmed in pulmonary artery endothelial cell cultures of 
PAH patients [57]. Increased cytosolic Ca2+ also modu-
lates eNOS function mainly by phosphorylation of 
eNOS (at Ser1177) by calcium-calmodulin dependent 
protein kinases [58]. Nevertheless, a recent study has 
demonstrated that lower expression of mitochondrial 
voltage-dependent anion channel-1 may inhibit the ac-
tivity of eNOS by regulating calcium ion transport in 
PAH patients [59].  
Low NO levels contribute to increased vascular tone 
in PAH. However, it may also be responsible for other 
pathological processes of this disease. For instance, NO 
can induce VEGF formation [43] as low levels of this 
molecule were associated with poorer right heart func-
tion [60]. Nitric oxide can also inhibit thrombus forma-
tion [61], thus reduced levels contribute to the in-
creased tendency of in situ thrombosis observed in 
PAH [24]. Nitric oxide can also inhibit vascular 
smooth muscle proliferation and migration via iNOS 
[62]. Finally, NO has anti-proliferative effect as well 
by blocking the transforming growth factor-β1 signal 
[63]. 
The dysregulation of NO signalling in PAH has 
been extensively discussed in other review publications 
[64, 65]. 
2.3. Exhaled NO in PAH  
Endogenous nitric oxide production can be analysed 
in exhaled breath samples [66]. However, to what ex-
tent the NO produced in the pulmonary vessels con-
tributes to fractional exhaled nitric oxide (FENO) lev-
els [67] as most of it rapidly reacts with haemoglobin 
and is transported in the circulation is discussed [68]. 
Nitric oxide is the most validated biomarker in exhaled 
breath, as it has been investigated in various pulmonary 
and non-pulmonary diseases. Apart from the diseased 
conditions, several factors affect its concentration in 
exhaled air [66, 69, 70]. 
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Most importantly, as FENO levels are influenced by 
the expiratory flow rate [69], the European Respiratory 
Society/American Thoracic Society (ERS/ATS) rec-
ommendations [70] and later the ERS Task Force tech-
nical standard document [66] suggested measuring ex-
haled nitric oxide at 50 ml/s during single expiratory 
manoeuvre. It has also been acknowledged that by 
measuring exhaled NO at different flows, bronchial NO 
production (JawNO) and alveolar NO concentration 
(CANO) can be calculated [77]. 
All three NOS isoforms can contribute to FENO 
values, albeit of different quantities. In healthy sub-
jects, exhaled nitric oxide mainly originates from 
eNOS and nNOS, while higher levels observed in in-
flammatory airway diseases, such as asthma or obstruc-
tive sleep apnoea [78], are most likely due to increased 
iNOS activity [67]. FENO data must be interpreted 
carefully, as various physiological and lifestyle factors 
contribute to mild changes. For instance, FENO is af-
fected by the clinical characteristics, such as age, gen-
der, height and weight [79-81], physical exercise [82], 
diet [83] or menstrual cycle [84] and most importantly 
smoking [85]. An analytical variance within [86, 87] 
and between [87, 88] different FENO devices should 
also be noted. These analytical and physiological vari-
ances have to be acknowledged when interpreting 
FENO data in pulmonary hypertension.  
Kaneko et al. recruited 8 patients with primary PAH 
(currently classified as idiopathic or heritable PAH) 
and 8 controls. They measured intrabronchial exhaled 
NO via a bronchoscope during tidal breathing and re-
ported lower levels in patients [71]. Intrapulmonary 
NO levels did not correlate with disease onset or sever-
ity [71]. 
Ozkan et al. did not find any difference in exhaled 
NO concentrations measured with the tidal breathing 
method among 21 patients with primary PAH, 11 pa-
tients with secondary pulmonary hypertension (seven 
with PAH due to congenital heart disease, portal hyper-
tension or scleroderma, three patients from group 4 and 
one patients with group 3 disease) and nine controls 
[72]. However, when patients receiving epoprostenol 
were excluded, exhaled NO levels were significantly 
lower in the primary PAH group.  
Cremona et al. measured exhaled nitric oxide with 
the tidal breathing method in 8 patients with primary 
PAH and 20 controls [89]. Exhaled NO production 
rather than its concentration was estimated. Patients 
with PAH had lower rate of production (2.85±0.7 
nmol/l/min) compared to controls (4.69±0.35 
nmol/l/min) which were related to altered diffusion 
capacity [89]. Similarly, Riley et al. estimated exhaled 
NO production in 9 patients with primary PAH and 20 
controls [90]. In contrast to the previous findings, this 
study did not show any difference between the two 
groups [90]. Archer et al. investigated exhaled nitric 
oxide in nine patients with anorexigen-associated PAH, 
8 subjects with primary PAH and 12 controls using the 
tidal breathing method [91]. Interestingly, FENO levels 
(not reported) and NO production was higher in pri-
mary PAH (198±79 nL/min) than in controls (40±10 
nL/min) or anorexigen-related PAH (61±16 nL/min) 
without a difference between the latter two groups [91]. 
Kharitonov et al. compared 67 control individuals 
with 23 patients with systemic sclerosis (6 of them had 
PAH) [73]. Exhaled NO levels were measured at 500 
ml/min flow (8.3 ml/s). FENO levels were lower in 
patients with pulmonary hypertension compared to the 
other two groups, and correlated with diffusion capac-
ity, but not with PAP or arterial oxygen levels [73]. 
Girgis et al. studied exhaled NO levels at various 
flow rates in 5 patients with primary PAH, 20 healthy 
subjects and 20 patients with scleroderma (5 of them 
had pulmonary hypertension) [75]. There was no dif-
ference in FENO measured at any flow rate or JawNO 
among the groups. While there was no difference in 
CANO between the primary PAH and control groups, 
CANO in patients with scleroderma and pulmonary 
hypertension was elevated [75]. Interestingly, when all 
scleroderma patients were analysed together, CANO 
levels were higher than in controls suggesting that the 
increase in alveolar NO may be due to scleroderma and 
not pulmonary hypertension itself [75]. The same 
workgroup evaluated FENO at multiple flow rates in 
10 patients with PAH (8 idiopathic, 2 anorexigen-
associated) and 12 controls [76]. FENO concentrations 
were reduced in PAH compared to controls, while there 
was no difference in CANO [76]. 
Cao et al. studied FENO at various expiratory flow 
rates in 115 patients with SSc (25 with PAH) and 84 
control subjects [74]. There was no difference in FENO 
between the groups at any flow rate or in JawNO, nor 
was there any correlation between FENO and the pul-
monary arterial pressures. CANO in pulmonary hyper-
tension was significantly higher compared to both con-
trol groups [74]. 
Malerba et al. investigated 50 patients with systemic 
sclerosis (12 with PAH) and 40 control subjects [92]. 
FENO was significantly higher in patients (11.7±8.1 
ppb vs 9.0±2.1 ppb in controls). Within the systemic 
sclerosis group, patients with PAH had lower FENO 
values (10.5±4.1 ppb) compared to those without PAH. 
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A significant inverse correlation between FENO and 
systolic PAP was noted [92]. Rolla et al. studied 47 
patients with SSc and 30 controls [93]. Similarly to the 
study by Malerba et al. [92], patients with systemic 
sclerosis had higher FENO levels (16.6±9.1 ppb) than 
controls (9.9±2.9 ppb). In contrast, subjects with SSc-
PAH (n=16) had lower FENO values (10.7±5.9 ppb) 
compared to those without PAH. FENO levels in-
versely correlated with PAP [93]. For the latter two 
studies, no comparison was made between the PAH 
and control groups [92, 93].  
Akbay et al. surveyed 19 patients with PAH (13 
with IPAH), 12 patients with chronic thromboembolic 
pulmonary hypertension (CTEPH) and 80 healthy con-
trols for 6 months [94]. When all patients with PH were 
analysed together (n=31), they had lower FENO 
(16.5±6.7 ppb) compared to controls (19.8±7.7 ppb). In 
the PH group, there was a significant correlation be-
tween FENO and tricuspid annular plane systolic ex-
cursion, a marker for right heart function. Interestingly 
when patients within the PAH group were divided into 
IPAH and associated PAH subgroups, FENO levels in 
the IPAH group were higher (18.5±6.7 ppb vs. 
12.8±4.3 ppb). No comparison has been made between 
the IPAH and control groups [94]. There was no differ-
ence between the baseline and the 6-month FENO val-
ues in any group.  
Malinovschi et al. studied FENO at multiple flow 
rates in 22 patients with PH (PAH: n=13, groups 2-4: 
n=9) and 21 healthy controls [95]. There was no differ-
ence in FENO (data were not presented), JawNO or 
CANO between patients and controls. When PAH was 
compared to other forms of PH, significantly lower 
FENO values were obtained, however, they were not 
different from the healthy controls. Interestingly, 
JawNO was lower, while CANO was higher in PAH 
compared to health [95].  
Carpagnano et al. investigated 24 patients with PH 
(10 PAH, 11 PH associated with COPD and 3 patients 
with PH due to left heart disease) [96]. FENO was 
measured according to the ERS/ATS recommendations 
at 50 ml/s [70] and also at different flows to estimate 
alveolar NO concentration. The authors did not find a 
significant difference between the three groups of pa-
tients for FENO values measured at 50 ml/s. Interest-
ingly, CANO values were higher in PAH and PH asso-
ciated with COPD than in patients with left heart dis-
ease. FENO or CANO levels did not correlate with any 
of the clinical variables. 
Machado et al. prospectively investigated 17 pa-
tients with IPAH treated with appropriate medications 
(prostacyclin analogues: n=16, calcium-channel 
blocker: n=1), 5 of whom died during the 2 years of 
follow-up [97]. There was no difference in FENO be-
tween the survivors and those who died. Baseline 
FENO correlated with overtime PAP drop and some 
increase in FENO was noted in the surviving patients' 
overtime [97].  
In summary of the exhaled nitric oxide studies, 
PAH was associated with lower [71, 73, 76, 89], simi-
lar [72, 74, 75, 90, 95] or elevated FENO levels or pro-
duction compared to health [91]. In the studies investi-
gating systemic sclerosis, the number of patients with 
PAH was relatively low and they were rarely compared 
with control subjects. FENO levels in SSc patients with 
PAH tended to be lower than those without [92, 93]. 
When evaluating alveolar NO concentrations in PAH, 
higher [74, 75, 95] or similar [76] values were obtained 
compared to health.  
These discrepancies can be explained by methodo-
logical differences discussed above (i.e. tidal breathing 
vs. single breath, various expiratory flows) and the ae-
tiological heterogeneity within the PAH group (i.e. 
IPAH or systemic sclerosis-associated). Nevertheless, 
even in studies showing reduced FENO in PAH, the 
differences are small and cannot easily be reproduced. 
Interestingly, while lower FENO levels are concluded 
as the reason for impaired eNOS activity, higher 
CANO values, which should more closely represent 
pulmonary vascular NO production than the FENO, are 
usually attributed to perivascular inflammation. Table 2 
summarises the studies which compared FENO con-
centrations between patients with PAH and controls. 
Reviews for further reading in relation to FENO and 
patients with PAH can be suggested [67, 98].  
There are limited data on the dynamics of FENO in 
animal models of PAH. It was clearly shown that only 
iNOS is responsible for the changes in FENO in mice 
without pulmonary disease or airway inflammation 
[99]. In rodent models of airway inflammation, ele-
vated FENO levels correlated with inflammatory com-
ponents of the airways [100, 101]. Le Pavec et al. were 
the first to determine FENO in monocrotaline-induced 
PAH model [102]. In their study, common bile duct 
ligation (CBDL) was also performed to induce hepatic 
cirrhosis in the rats after monocrotaline injection. 
FENO levels were lower in MCT rats compared to the 
controls due to decreased pulmonary eNOS expression. 
CBLD led to improved survival and decreased total 
pulmonary resistance in MCT rats, and it was associ-
ated with elevated FENO levels as a result of upregu-
lated eNOS and iNOS in the lungs. The authors con-
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cluded that cirrhosis may be protective against PAH 
[102]. Strobl et al. focused on FENO levels in a pneu-
monectomy-monocrotaline rat model of PAH using a 
new mathematical modification of FENO measurement 
to calculate exhaled NO output in time [103]. In con-
trast to the previous study, they found no difference in 
FENO in this PAH model. However, low basal exhaled 
NO output (21.21 ± 8.27 ppb/h) increased twenty-eight 
days after monocrotaline injection (23.96 ± 7.60 ppb/h) 
when PAH was established. Interestingly, L-arginine 
and BH4 combination therapy led to decreased mPAP 
and elevated exhaled NO output, but it had no effect on 
FENO. A significant inverse correlation was detected 
between exhaled NO output and mPAP in animals with 
PAH before and also after therapy, suggesting a possi-
ble role for this marker in PAH models [103]. Further 
investigations are needed to evaluate the utility of 
FENO measurements in animal models.  
2.4. Other Biomarkers of the Altered NO Pathway 
in PAH 
Asymmetric dimethyl-arginine (ADMA) is a com-
petitive antagonist of L-arginine for NOS, and it is in-
volved in the regulation of NO signalling in the cardio-
vascular system [104]. The main source of circulating 
ADMA is through the metabolism of methylarginines 
in the lungs [105]. Serum ADMA concentration was 
increased in patients with untreated PAH (most patients 
had IPAH) compared to age- and gender-matched con-
trol subjects [106]. Moreover, plasma ADMA concen-
trations negatively correlated with measures of right 
ventricular function (including cardiac index and right 
atrial pressure) and survival in patients with PAH 
[107]. ADMA also proved to be an independent predic-
tor of survival. In line with this, the same study de-
scribed that the intravenous administration of ADMA 
increased PVR and lowered stroke volume in healthy 
volunteers.  
Similarly, circulating ADMA concentration in pa-
tients with PAH associated with congenital heart dis-
ease (CHD) was higher than in controls and in patients 
with no PAH, but no change was noted compared to 
patients with idiopathic PAH [108, 109]. Interestingly, 
ADMA levels in PAH showed a close positive correla-
tion to mPAP and PVR in both subgroups of PAH sug-
gesting a role for ADMA for risk assessment of pa-
tients [106, 110]. Importantly, plasma ADMA is re-
sponsive to specific treatment as biomarker levels were 
decreased six months of PDE-5 inhibitor (sildenafil) 
therapy of patients with PAH due to CHD [110]. Fur-
thermore, ADMA might be useful to screen for PAH 
among subjects with SSc, as a circulating ADMA con-
centration above 0.7 µM showed good sensitivity and 
specificity to identify PAH in this patient group [111]. 
In addition, an elevated plasma ADMA concentration 
was also associated with the development of PAH 
among patients with human immunodeficiency viral 
infection [112].  
Although ADMA production is increased primarily 
by hypoxia [113], it is also generated in response to 
inflammation [104]. A potential explanation for raised 
ADMA levels in PAH could be the decreased expres-
sion of dimethylaminohydrolases (DDAH), which are 
responsible for ADMA degradation. In support, re-
duced DDAH levels were found in the lungs of patients 
with IPAH [114]. As mentioned before, BH4 deficiency 
can lead to NOS uncoupling. Supporting this, inhibi-
Table 2. FENO concentration in patients with PAH and control subjects. 
Patients with PAH Controls 
N FENO, ppb N FENO, ppb 
Direction of differ-
ences in PAH Comments Reference 
7 2.8±0.9 8 8±1 ↓ Exhaled NO was meas-ured intrabronchially Kaneko et al. [71] 
21 10±1.3 9 6.6±0.6 ↔ 
Exhaled NO was meas-
ured with the tidal 
breathing method 
Ozkan et al. [72] 
6 20±6 67 80±7 ↓ FENO was measured at 8.3 ml/s Kharitonov et al. [73] 
21 19±12 84 21±11 ↔  - Cao et al. [74] 
5 20.2±6.5 20 26±3 ↔  - Girgis et al. [75] 
10 11±2 12 17±2 ↓  - Girgis et al. [76] 
Data are shown as mean±standard deviation. FENO: fractional exhaled nitric oxide, N: number of subjects included in the study, PAH: pul-
monary arterial hypertension, ppb: particles per billion, ↔ refers to no difference. 
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tion of BH4 synthesis was associated with the devel-
opment of pulmonary hypertension in mice [50]. 
The concentration of plasma L-arginine, a substrate 
for NOS, was lower in treatment naïve patients with 
PAH than in patients with PH due to left heart disease 
implying a more severe deficiency of NOS functional-
ity in the former group [115]. Of note, L-arginine lev-
els showed a positive correlation to 6-minute walking 
distance (6MWD) and a higher L-arginine/ADMA was 
related to better World Health Organization (WHO) 
functional class in PAH. In an earlier study, plasma 
levels of L-arginine also closely correlated to cardiac 
output, right atrial pressure and functional parameters 
[116].  
The combined plasma levels of nitrate and nitrite 
(NOx) were decreased in 104 patients with treatment 
naïve IPAH compared to healthy controls [117]. Inter-
estingly, biomarker concentration was even lower in 
the hereditary form (mutations in the BMPR2 gene), 
than in the idiopathic type. NOx levels correlated nega-
tively with mPAP, PVR and cardiac output. Of signifi-
cance, patients with plasma NOx concentration ≤ 10 
µM presented with worse survival and this biomarker 
was an independent predictor of increased risk for mor-
tality. In line with this, urinary NOx concentration was 
lower in patients with PAH compared to controls, and 
it was normalized by 3 months of treatment with 
bosentan [76]. These data further support that abro-
gated NO signalling is a major step in the pathomecha-
nism of PAH.  
Nitric oxide in the circulation rapidly forms S-
nitrosothiol (SNO) as it binds to the cysteine residue on 
the β globin chain of haemoglobin (Hb) in red blood 
cells. NO is released as a result of the conformational 
switch of haemoglobin during deoxygenation to modu-
late local blood flow [118]. SNO-Hb ratio was consid-
erably decreased in patients with moderate to severe 
untreated PAH having hypoxaemia and showed an in-
verse relationship to mPAP. As a functional conse-
quence, red blood cells from patients induced an at-
tenuated vasodilatory response of the pulmonary artery 
in vitro [121].  
Endothelial nitric oxide synthase (eNOS) generates 
NO and L-citrulline from L-arginine in the vascular 
endothelium. In the medial layer NO binds to a heme 
on the β-subunit of the soluble guanylyl cyclase (sGC), 
which produces cyclic guanylyl monophosphate 
(cGMP) from guanosine triphosphate (GTP). cGMP 
negatively regulates intracellular calcium stores 
through protein kinase G. Calcium binds calmodulin to 
phosphorylate the myosin light chain kinase (MLCK-
p), which subsequently phosphorylates the myosin 
light-chain (MLC-p) leading to smooth muscle contrac-
tion. Phospodiesterase-5 (PDE-5) hydrolyses cGMP 
and shifts the balance to an increased vascular tone. 
The inhibitors of PDE-5 (sildenafil, tadalafil) promotes 
cGMP signalling and vasorelaxation, but it requires the 
presence of NO-sGC [119]. The sGC stimulator rio-
ciguat activates sGC both independently and in synergy 
with NO [120]. Adapted from Toshner et al. [119]  
3. THE THERAPEUTIC MODULATION OF THE 
PULMONARY VASCULAR NO PATHWAY AND 
FENO IN PAH  
3.1. Pharmacodynamics and Clinical Efficacy of 
PDE-5 Inhibitors 
Phosphodiesterase enzymes are responsible for the 
cytosolic degradation of cyclic adenosine monophos-
phate (cAMP) and cyclic guanosine monophosphate 
(cGMP). Several PDE isoforms have been described in 
a wide range of tissues [122]. Phosphodiesterase iso-
type-5 (PDE-5) is expressed in vascular smooth muscle 
cells of the lung [123, 124] and it is the major regulator 
of pulmonary vascular tone. PDE consists of two major 
domains, catalytic C-domain and regulatory R-domain. 
The binding of cGMP by the allosteric site of R-
domain enhances the catalytic activity in C-domain 
resulting in increased cGMP degradation [125]. The 
upregulation of PDE-5 expression and activity has been 
identified in PAH generating low cGMP levels and 
consequential vasoconstriction in the pulmonary vascu-
lature [126]. Competitive and reversible inhibition of 
catalytic C-domain by sildenafil and vardenafil is based 
on their similar molecular structures with cGMP [127]. 
Thus PDE-5 inhibitors preserve cGMP levels in the 
pulmonary arteries [128]. It is noteworthy that PDE-5 
inhibitors act in a NO-dependent manner because the 
absence of endogenous NO impairs sGC function re-
sulting in decreased cGMP levels [129] (Fig. 2). Silde-
nafil and tadalafil are approved for the treatment of 
PAH by European Medicines Agency and US Food and 
Drug Administration and vardenafil is currently being 
studied for PAH therapy [1, 130]. Besides their pulmo-
nary vasodilatory effects, PDE-5 inhibitors have been 
shown to modulate vascular remodelling as they exert 
antiproliferative and apoptotic effects on smooth mus-
cle cells via cGMP signalling [131, 132]. 
The SUPER-1 (Sildenafil Use for Pulmonary Arte-
rial Hypertension), a multicentre placebo-controlled 
double-blind study included 278 patients with PAH 
receiving sildenafil for 12 weeks [133]. Sildenafil 
treatment demonstrated a significant decrease in mPAP 
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and PVR and improved cardiac index and WHO func-
tional class. However, the time to clinical worsening 
was not significantly affected by sildenafil compared to 
the placebo group [133]. During the 3-year follow-up 
of the same cohort, a considerable improvement in 
functional capacity was noted with a favourable overall 
survival rate of 79% [134]. The clinical efficacy of ta-
dalafil was evaluated in PHIRST study (Pulmonary 
Arterial Hypertension and Response to Tadalafil) 
[135]. The functional capacity of patients receiving 
tadalafil, as measured by the 6MWD, improved in a 
clinically meaningful extent, and a longer time to clini-
cal worsening and a better quality of life were found 
compared to placebo treatment. The favourable effect 
of tadalafil on the 6MWD was maintained by 52 weeks 
of therapy [136]. Furthermore, PDE-5 inhibitors were 
associated with a significant reduction in mortality in 
some [137], but not all meta-analyses [138, 139]. In 
addition, Coeytaux et al. found a significant decrease in 
the rate of hospitalization associated with PDE-5 in-
hibitors [138]. PDE-5 inhibitors have a mild-to-
moderate and dose-dependent side effect profile [128], 
with adverse effects mostly related to vasodilatation, 
such as visual disturbance, headache, flushing, dyspep-
sia and limb pain [139].  
3.2. Pharmacodynamics and Clinical Efficacy of 
sGC Stimulators 
The soluble guanylate cyclase is a cytosolic en-
zyme, which is responsible for the conversion of GTP 
to cGMP (Fig. 2). cGMP is an important second mes-
senger of NO, thus its decreased level results in inap-
propriate vasodilatation. Moreover, cGMP itself has 
vasodilator, anti-inflammatory and antithrombotic ef-
fects and it also inhibits the proliferation and fibrosis of 
vascular smooth muscle cells [140]. Soluble guanylate 
cyclase has a heterodimeric structure with two 
subunits. Under the physiological state, the smaller β-
subunit contains a reduced heme with a ferrous iron 
(Fe2+), where NO binds to and enhances sGC activity 
by 400 folds resulting in high intracellular cGMP levels 
[141]. However, under oxidative stress usually present 
in PAH, the heme iron is converted into an oxidized 
form, and NO binding is abrogated. Thus, the stimula-
tion of sGC and the subsequent increase in cGMP con-
centration is a major therapeutic target in PAH. The 
sGC stimulator riociguat has been approved for the 
treatment of PAH and CTEPH [1, 130, 142]. After 
binding the sGC-NO-heme complex, riociguat causes a 
dose-dependent increase in sGC activity in two ways. 
On one hand, via synergy with NO, it potentiates sGC-
NO signalling by stabilizing the sGC-NO-heme com-
plex. Thus, it sensitizes the enzyme to the low avail-
ability of endogenous NO, which is an important com-
ponent of PAH pathomechanism. On the other hand, it 
directly stimulates sGC through NO-independent 
mechanisms [143]. 
Preclinical animal studies reported that riociguat 
promotes vasorelaxation, moreover it has antifibrotic, 
antiproliferative and antithrombotic effects [120]. Rio-
ciguat induced more potent vasodilatation than silde-
nafil in human and rat pulmonary arteries in vitro 
[144]. Moreover, vasodilatation associated with rio-
ciguat was 3-fold stronger in hypoxia than under nor-
moxia [144]. In hypoxia-induced PAH combined with 
VEGF receptor blockade in a rat model, the improve-
ment in haemodynamic parametres, attenuated right 
heart hypertrophy and the reversal of structural changes 
was described after riociguat therapy [120, 145].  
The PATENT-I study (Pulmonary Arterial Hyper-
tension Soluble Guanylate Cyclase–Stimulator Trial 1) 
included 443 patients with symptomatic PAH [146], 
who were treatment-naïve or treated with endothelin-
receptor antagonists or prostanoids before. Compared 
to placebo, 12 weeks of therapy with riociguat resulted 
in a decrease in PVR and serum brain natriuretic pep-
tide level, and an increase in 6MWD and functional 
class [146]. In the extended PATENT-II study, the im-
provement in 6MWD further increased and functional 
class improved in 33% of patients [147]. The combina-
tion of sildenafil and riociguat treatment did not yield 
an improvement in either pulmonary haemodynamics 
or clinical parameters, however, an increased incidence 
of adverse effects was noted. [148]. Due to its lack of 
lung specificity, the side effects of riociguat are attrib-
uted to its systemic arterial vasodilator effects such as 
hypotension, dizziness, haemoptysis or syncope [146].  
Recent publications give further details of clinical 
trials and efficacy of drugs modulating the NO pathway 
in PAH [149, 150]. 
3.3. PAH Therapy and FENO 
Effects of PAH therapies on FENO have been pre-
viously investigated in a few studies (Table 3). In the 
study of Girgis et al., PAH patients showed lower lev-
els of FENO compared to the control group. After hav-
ing taken oral bosentan for 3 months FENO concentra-
tions were increased and normalized to control levels 
[76]. The effects of parenteral epoprostenol or 
treprostinil on FENO levels were discussed by 
Machado et al. FENO was measured in 17 PAH pa-
tients before and after treatment. After 24 months of 
therapy, FENO showed a 2-fold increase in survivors
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Table 3. The effect of drugs with clinical benefit on FENO concentration in patients with PAH. 
Patients Treatment FENO, ppb 
N PAH subgroup Drug Duration Before After 
Reference 
10 IPAH, anorexigen-induced bosentan 3 months 33±11 105±44* Girgis et al. [76] 
17 IPAH, HPAH, portopulmonary PH, SSc-associated, CHD-related 
prostacyclin analogue or 
CCB 
24 months 8±1 15±1*# Machado et al. [97] 
21 SSc-related PDE-5i, ERA, prostacy-cylin analogue 4 months 16.4 16.6 
Cao et al. 
[74] 
4 IPAH, HPAH epoprostenol infusion 24 hours 10±2 15±2§ Ozkan et al. [72] 
15 IPAH, CTD-associated, anorexigen-induced beetroot juice 1 week 
17.56 /95% CI 11.16–
26.43/*& 
Henrohn et 
al. [153] 
Data are shown as mean or mean±standard deviation. After: following the course of therapy. Before: prior to drug therapy. CCB: calcium-
channel blocker, CI: confidence interval, CHD: congenital heart disease, CTD: connective tissue disease, ERA: endothelin receptor antago-
nist, FENO: fractional exhaled nitric oxide, IPAH: idiopathic PAH, HPAH: heritable PAH, N: number of patients included in the study, PAH: 
pulmonary arterial hypertension, PDE-5i: phosphodiesterase-5 inhibitor, ppb: particles per billion, SSc: systemic sclerosis. *p<0.001, §p<0.05 
vs. before, &median of differences between placebo treatment and beetroot juice ingestion, #only in the 12 survivors.  
 
and correlated with the decrease in systolic PAP [97]. 
In addition, NO concentration measured in breath col-
lected with tidal breathing was increased 24 hours after 
epoprostenol infusion in patients with PAH [72].  
On the contrary, therapy with PDE-5 inhibitors has 
not proven to influence FENO. Rothe et al. evaluated 
the changes in expiratory NO concentrations after 
treatment with sildenafil in 10 healthy volunteers. Par-
ticipants received 50 mg sildenafil monotherapy or pla-
cebo on the first and the seventh day. Exhaled NO was 
unchanged 1 h, 24 h and 72 h after sildenafil intake 
[151]. In a recent study by Cao et al., exhaled NO was 
measured in patients with SSc-PAH. Specific PAH 
therapies included monotherapies with oral sildenafil, 
tadalafil, ambrisentan, bosentan and inhaled treprostinil 
and the combination of tadalafil and ambrisentan. After 
4 months of these therapies no significant change was 
detected either in CANO or JawNO [74]. In the future, 
further investigations are needed to clarify the role of 
PAH therapies in FENO changes.  
3.3. Other Pharmacological Strategies 
Besides the effective targeted therapeutic options, 
non-specific pharmacological strategies have also been 
applied to modulate the pulmonary NO pathway in pa-
tients with PAH under experimental settings. These 
interventions aim to either induce the NOS-dependent 
or NOS-independent pulmonary NO generation. A 
short course of oral L-arginine supplementation in pa-
tients with pre-capillary PH resulted in enhanced NO  
 
production as demonstrated by the increased plasma 
levels of L-citrulline, the end-product of NOS activity. 
Of note, L-arginine administration decreased mPAP 
and PVR, and improved exercise capacity without in-
ducing clinically significant hypotension [152]. 
A strategy is to improve the NOS-independent pro-
duction of pulmonary NO is through the induction of 
the nitrate-nitrite-NO pathway. On one hand, NO has a 
short half-life, and in aqueous solutions, it is decom-
posed to nitrite, while in tissues NO and nitrite are en-
zymatically oxidized to nitrate [154]. In addition, die-
tary inorganic nitrate can be transformed into nitrite by 
commensal oral bacteria [155]. On the other hand, ni-
trite can serve as a pool for NO as it can be converted 
into NO by deoxyhemoglobin-mediated reduction 
[156]. Furthermore, various human enzymes with ni-
trite reductase activity under certain conditions such as 
hypoxia and acidosis have been proposed, including 
xanthine oxidoreductase, aldehyde oxidoreductase, cy-
tochrome C, deoxymyoglobin, and carbonic anhydrase 
[157]. 
In line with this, patients with PAH received nitrate-
rich beetroot juice as a dietary supplement for one 
week, which resulted in an increase in FENO, CANO 
and JawNO, and elevated levels of plasma and salivary 
nitrate and nitrite. Importantly, those patients with at 
least 30% rise in plasma nitrite presented with an im-
provement in exercise capacity [153]. These positive 
effects were seen, although most patients received 
treatment with a PDE-5 inhibitor. 
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Furthermore, the inhalation of sodium nitrite re-
sulted in a decrease in mPAP and right atrial pressure 
in patients with PAH, and the therapy was well-
tolerated. Importantly, there was no change in cardiac 
output, but mean systemic arterial pressure decreased 
significantly [158]. Of note, nitrite inhalation was asso-
ciated with an acute 4-5-fold elevation of FENO in 
healthy subjects [159], which was not apparent 30 
minutes after the dose.  
CONCLUSION  
Several experimental and human studies prove the 
crucial involvement of the attenuated endothelial NO 
signalling of the pulmonary vasculature in the path-
omechanism of PAH. This is also supported by circu-
lating biomarkers such as the increased concentration 
of ADMA or the reduced levels of NO metabolites. 
However, studies on exhaled NO (both bronchial and 
alveolar readouts), which have the potential to more 
directly assess pulmonary vascular processes, show 
ambiguous results for differentiating disease from 
health. These discrepancies can be due to unstandard-
ized measurement protocols, the low number of pa-
tients, various aetiologies of PAH in patient groups, 
and probably the ignorance of factors confounding NO 
readings. Studies on the potential of exhaled NO to 
predict survival are also lacking.  
PDE-5 inhibitors and sGC stimulators are available 
at high costs to induce pulmonary NO signalling and 
confer clinical efficacy in PAH. Currently, therapeutic 
decisions are made based on clinical and some labora-
tory findings. However, data exploring the capacity of 
exhaled NO or other markers of the NO pathway to 
predict response to these drugs are missing, and only a 
handful of studies have assessed the effects of PAH-
specific therapy on FENO, in general.  
In conclusion, although exhaled NO is easy to 
measure and it would be an attractive option for assess-
ing disease process in PAH, its current role in aiding 
the diagnosis or guiding the treatment is unclear. Mul-
ticentre studies recruiting a homogenous group with 
increasing number of patients are needed in the future 
to explore the applicability of bronchial and alveolar 
NO parameters in disease assessment.  
LIST OF ABBREVIATIONS 
6MWD = 6-minute walking distance 
ADMA = Asymmetric dimethylargin-
ine 
Akt/PKB = Protein kinase B 
ATS = American Thoracic Society 
BH4 = Tetrahydrobiopterin 
BMPR2 = Bone morphogenetic protein 
receptor II 
Ca2+ = Calcium 
cAMP = Cyclic adenosine monophos-
phate 
CANO = Alveolar NO concentration 
CaSR = Calcium sensing receptor 
CBDL = Common bile duct ligation 
CCB = Calcium-channel blocker  
cGMP = Cyclic guanosine monophos-
phate 
CHD = Congenital heart disease  
CHD-related  
PAH = Congenital heart disease re-
lated pulmonary arterial hy-
pertension 
CI  = Confidence interval 
COPD = Chronic obstructive pulmo-
nary disease 
CTD = Connective tissue disease  
CTD-associated  
PAH = Connective tissue disease 
associated pulmonary arterial 
hypertension 
CTEPH = Chronic thromboembolic 
pulmonary hypertension 
DDAH = Dimetylaminohydrolase 
ERA = Endothelin receptor antago-
nist 
ERS = European Respiratory Soci-
ety 
Fe2+ = Ferrous ion 
FENO = Fractional exhaled nitric ox-
ide 
GMP = Guanosine monophosphate 
GTP = Guanosine triphosphate 
Hb = Haemoglobin 
HIV = Human immunodeficiency 
virus 
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HPAH = Heritable pulmonary arterial 
hypertension 
IPAH = Idiopathic pulmonary arterial 
hypertension 
JawNO = Different flows bronchial NO 
production 
MCT = Monocrotaline 
MLC-p = Myosin light-chain 
MLCK-p = Myosin light chain kinase 
mPAP = Mean pulmonary artery pres-
sure  
NO = Nitric oxide  
NOS = Nitric oxide synthase 
NOS1=nNOS = Neuronal nitric oxide syn-
thase 
NOS2=iNOS = Inducible nitric oxide syn-
thase 
NOS3=eNOS = Endothelial nitric oxide syn-
thase 
NOx = Combined plasma levels of 
nitrate and nitrite 
PAH = Pulmonary arterial hyperten-
sion 
PAP = Pulmonary artery pressure  
PATENT-I = Pulmonary Arterial Hyper-
tension Soluble Guanylate 
Cyclase–Stimulator Trial 1 
PATENT-II = Pulmonary Arterial Hyper-
tension Soluble Guanylate 
Cyclase–Stimulator Trial 2 
PDE-5 = Phosphodiesterase isotype-5  
PDE-5i = Phosphodiesterase-5 inhibitor 
PH = Pulmonary hypertension 
PHIRST = Pulmonary Arterial Hyper-
tension and Response to Ta-
dalafil 
ppb = particles per billion 
PVR = Pulmonary vascular resis-
tance 
Ser1177 = Serine 1177 
sGC = Soluble guanylate cyclase 
SNO = S-nitrosothiol 
SSc = Systemic sclerosis  
SSc-PAH = Systemic sclerosis-related 
pulmonary arterial hyperten-
sion 
SUPER-1 = Sildenafil Use for Pulmonary 
Arterial Hypertension 
Thr495 = Threonine 495 
VEGF = Vascular endothelial growth 
factor 
WHO = World Health Organization 
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